Sexual Dysfunction, Physiological Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo Controlled, Crossover Trial on Safety and Efficacy of Autologous Platelet-Rich Plasma for Treatment of Peyronie's Disease
The purpose of this study is to learn about the effects of Platelet-Rich Plasma (PRP) injection in men with Peyronie's Disease (PyD).
Status | Recruiting |
Enrollment | 80 |
Est. completion date | July 1, 2024 |
Est. primary completion date | July 1, 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Be Male 2. Be 18 to 75 years of age (inclusive). 3. Be able to provide written informed consent 4. Have a diagnosis of PD with evidence of active or stable disease as determined by the investigator 5. Penile curvature deformity of >30° to <120° 6. Agree to comply with all study related tests/procedures. Exclusion Criteria: 1. Previous penile surgery of any kind (except circumcision and condyloma removal), such as penile lengthening, penile cancer surgery, penile plication, grafting. 2. Previous intralesional injection therapy (such as Xiaflex) for PD. 3. Previous history of priapism or penile fracture 4. PD characterized by a ventral plaque 5. Severe erectile dysfunction as characterized with an International Index of Erectile Function (IIEF) score = 16 6. Actively on anticoagulation during time frame of injections (aspirin 81 mg will be eligible for therapy) 7. Hour-glass deformity 8. Unwilling to participate 9. Medically unfit for sexual intercourse as deemed by the principal investigator 10. Patients scheduled to undergo an elective medical procedure during the investigation timeframe that will interfere with autologous PRP injection therapy. 11. Have a serious comorbid illness/condition/behavior that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study. |
Country | Name | City | State |
---|---|---|---|
United States | University of Miami | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Miami |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of subjects in each group who attain degree change in penile curvature. | Treatment efficacy of PRP will be assessed via the percentage of participants achieving degree change in penile curvature from baseline. Degree of curvature will be measured using a goniometer with the aid of injection of vasoactive substance into the penis. | 7 months | |
Primary | Percentage of subjects achieving any decrease in PDQ sub-domain scores (Psychological and Physical Symptoms, Symptom Bother). | Treatment efficacy will be assessed via the percentage of participants achieving any decrease in Peyronie's disease Questionnaire (PDQ) sub-domain scoring from baseline. The sub-domains that will be assessed in primary outcome is Psychological and Physical Symptoms and Symptom Bother. PDQ is a validated 15-item questionnaire that assess Psychological and Physical Symptoms, Symptom Bother, and Penile Pain subdomains. The Psychological and Physical Symptoms subdomain is measured from 0 to 24 (most severe symptoms). Symptom Bother subdomain is measured from 0 to 30 (most severe pain). | 7 months | |
Secondary | Incidence of adverse events in all patients | Safety will be evaluated via the incidence of adverse events as assessed by treating physician | Baseline, 6 months (post-intervention) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01021670 -
An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride
|
Phase 4 | |
Completed |
NCT00324948 -
Topical Alprostadil for Female Sexual Arousal Disorder
|
Phase 2 | |
Recruiting |
NCT02624648 -
Effects of Lepidium Meyenii Walp on Sexual Function in Postmenopausal Women
|
Phase 1 | |
Completed |
NCT05692960 -
Women's Interventions for Sexual Health: WISH
|
N/A | |
Completed |
NCT01188720 -
Sexual Health on Antidepressants Through Physical Exercise
|
N/A | |
Completed |
NCT00692419 -
Pain, Sexual Dysfunction, and Depression in Hemodialysis Patients
|
N/A | |
Completed |
NCT01063881 -
The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy
|
Phase 3 | |
Completed |
NCT00451165 -
Bowel, Urinary and Sexual Function After Laparoscopic Colorectal Surgery
|
N/A | |
Recruiting |
NCT04604951 -
Below the Belt: Non-invasive Neuromodulation to Treat Bladder, Bowel, and Sexual Dysfunction Following Spinal Cord Injury
|
N/A | |
Completed |
NCT02381912 -
Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer
|
N/A | |
Completed |
NCT00443248 -
Vaginal Heat Wash-out (HWO) in 4 Groups of Women (Pre- and Postmenopausal With and Without Female Sexual Arousal Disorder (FSAD)).
|
Phase 1 | |
Completed |
NCT00698035 -
Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients
|
Phase 2 | |
Completed |
NCT00443027 -
Effect Of Menstrual Cycle On Vaginal Blood Flow In Pre-Menopausal Healthy Women.
|
Phase 1 | |
Completed |
NCT03241524 -
Consistency of Questionnaires to Evaluating Sexual Functions in Young Healthy Women
|
N/A | |
Terminated |
NCT03018106 -
Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction
|
Phase 4 | |
Completed |
NCT04364841 -
Body Image and Sexuality After Bariatric Surgery
|
||
Completed |
NCT03592121 -
Study to Investigate the Effect of AB-101 in Breast Cancer Survivors
|
Early Phase 1 | |
Completed |
NCT00482664 -
The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.
|
Phase 2 | |
Recruiting |
NCT05456919 -
Quality of Sexual Function in BRCA Mutated Women
|
||
Recruiting |
NCT06308614 -
Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women
|
Phase 2 |